Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients

Manon T. Huizing, Anther C F Keung, Hilde Rosing, Victor Der Van Kuij, Wim W. Ten Bokkel Huinink, Ingrid M. Mandjes, A. C. Dubbelman, Herbert M. Pinedo, Jos H. Beijnen

Research output: Contribution to journalArticle

Abstract

Purpose: To investigate the pharmacokinetics and pharmacodynamics of paclitaxel in a randomized comparative study with four different treatment arms in patients with platinum-pretreated ovarian carcinoma. Patients and Methods: Eighteen patients were entered onto this study in which paclitaxel was administered at a high dose of 175 mg/m2 versus a low dose of 135 mg/m2 on a 3- or 24-hour infusion schedule. A solid-phase extraction technique for sample pretreatment followed by a reverse-phase high-performance liquid chromatographic (HPLC) assay was used for analysis of plasma. Results: Grade 3 neutropenia occurred in all four treatment arms. However, it was more severe on the 24-hour infusion schedule. Paclitaxel concentrations as low as 0.012 μmol/L were measured with the HPLC assay. With this low quantitation threshold, we found the plasma disappearance of paclitaxel to be triphasic, with half-lives t1/2(α), t1/2(β), and t1/2(γ) mean values for the different treatment arms of 0.19 hours (range, 0.01 to 0.4), 1.9 hours (range, 0.5 to 2.8), and 20.7 hours (range, 4 to 65), respectively. Eleven possible metabolites were found, of which three were identified as taxanes by online HPLC-photodiode array (PDA) detection. Investigation of pharmacodynamics shows no clear relationship between the pharmacokinetic parameters area under the plasma concentration time curve (AUC), area under the plasma concentration moment curve (AUMC), maximal plasma concentration (Cmax), clearance, and toxicity. However, a relationship was found between the duration of plasma concentrations above a threshold of 0.1 μmol/ L with absolute neutrophil count (ANC) and white blood cell count (WBC). Conclusion: Paclitaxel is metabolized, and putative metabolic products can be found in plasma of patients treated with the drug. Our results indicate that myelosuppression can be predicted by the measurement of the duration of plasma concentrations above the threshold of 0.1 μmol/L.

Original languageEnglish (US)
Pages (from-to)2127-2135
Number of pages9
JournalJournal of Clinical Oncology
Volume11
Issue number11
StatePublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Huizing, M. T., Keung, A. C. F., Rosing, H., Van Kuij, V. D., Ten Bokkel Huinink, W. W., Mandjes, I. M., Dubbelman, A. C., Pinedo, H. M., & Beijnen, J. H. (1993). Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. Journal of Clinical Oncology, 11(11), 2127-2135.